A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

NCT ID: NCT07046780

Last Updated: 2025-07-02

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 90 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-07-30
• Study Completion Date: 2027-12-30

Brief Summary

This study is a prospective, observational, real-world, multi-center study planning to enroll 90 patients. The study will observe and document patients' actual clinical practices in receiving Iparomlimab and Tuvonralimab Injection (QL1706). The primary objectives are to evaluate the safety and effectiveness of Iparomlimab and Tuvonralimab Injection (QL1706) in treating locally advanced or metastatic solid tumors.

Conditions

Solid Tumor Cancer; Metastatic Solid Tumors; Locally Advanced

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Observation group

Patients treated with Iparomilimab and Tuvonralimab in the real world

Observation arm

Intervention Type: DRUG

To observe the efficacy and safety of Iparomilimab and Tuvonralimab in the treatment of patients with solid tumors in the real world

Interventions

Observation arm

To observe the efficacy and safety of Iparomilimab and Tuvonralimab in the treatment of patients with solid tumors in the real world

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1) Histologically or cytologically confirmed locally advanced or metastatic solid tumors with disease progression (radiographic or clinical) after ≥1 line of prior standard therapy, unsuitable for/intolerant to standard therapy. Includes but not limited to: Gastrointestinal tumors (colorectal cancer, hepatocellular carcinoma, esophageal cancer, biliary tract cancer, pancreatic cancer, gastric cancer), Breast cancer, Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC), Soft tissue sarcoma;
• 2) ECOG performance status 0-2;
• 3) ≥1 measurable lesion per RECIST v1.1 ;
• 4) Adequate organ function meeting ALL criteria below:

1. Hematology (without transfusion/G-CSF support within 7 days):

Absolute neutrophil count (ANC) ≥1.5×10⁹/L Platelets ≥100×10⁹/L Hemoglobin ≥90 g/L

2. Biochemistry :

Total bilirubin (TBIL) ≤2×ULN ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases present) Serum creatinine (Cr) ≤1.5×ULN Albumin ≥28 g/L

3. Urinalysis :

Urine protein <2+ (dipstick) If protein ≥2+, 24h urinary protein ≤1.0 g

4. Coagulation (without anticoagulants):

PT/APTT/INR ≤1.5×ULN

• 5) Life expectancy ≥12 weeks;
• 6) Contraception : Females of childbearing potential or males with partners of childbearing potential must use effective contraception during treatment and for 6 months post-treatment;
• 7) Signed informed consent and protocol compliance.

Exclusion Criteria

• 1) Tumor-Related Conditions

1. Known CNS metastases (except those radiologically stable ≥4 weeks after radiotherapy);

2. Other malignancies within past 5 years, excluding:

Cured basal/squamous cell skin cancer Localized low-risk prostate cancer Cervical/breast carcinoma in situ

3. Severe bone lesions from metastatic disease, including:

Uncontrolled bone pain Pathologic fractures at critical sites (within 6 months) or impending spinal cord compression;

4. Uncontrolled effusions requiring recurrent drainage (pleural/pericardial/ascites), per investigator assessment.

• 2) Prior Anti-tumor Therapy

1. Prior systemic therapy with CTLA-4 inhibitors or other ICIs;

2. Any anti-tumor treatment within 4 weeks before first dose, including:

Surgery/chemotherapy/palliative radiotherapy to non-target lesions/hormonal/targeted/biologic/immunotherapy;

3. Treatment-related toxicities not recovered to CTCAE grade ≤1 (exceptions: alopecia/platinum-induced neuropathy ≤ grade 2).

• 3) Comorbidities & History

1. Arterial thromboembolism within 6 months (MI/unstable angina/stroke/TIA);

2. Symptomatic heart failure (NYHA class III-IV), unstable angina, or uncontrolled arrhythmia;

3. Severe pulmonary disease : ILD/COPD/symptomatic bronchospasm;

4. Active uncontrolled infection (≥CTCAE grade 2), including:

HIV Active HBV (DNA ≥500 IU/mL) HCV (Ab+ with detectable RNA) HBV/HCV co-infection;

5. History of neurologic/psychiatric disorders;

6. Recent or current substance abuse;

7. Prior allogeneic organ/hematopoietic stem cell transplantation.

• 4) Hypersensitivity to study drug or its excipients.
• 5) Active autoimmune disease requiring treatment or history within 2 years. Exceptions: Vitiligo/alopecia/psoriasis not needing systemic therapy Hypothyroidism managed only with hormone replacement Type 1 diabetes controlled solely with insulin.
• 6) Pregnant/lactating women;
• 7) Any uncontrolled systemic disease increasing study risk (per investigator);
• 8) Other unsuitable conditions determined by investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

PENG YUAN

OTHER

Sponsor Role: lead

Responsible Party

PENG YUAN

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, , China

Countries

China

Central Contacts

Xue Wang

Role: CONTACT

wxyxyuki@163.com

86-010-87787242

Facility Contacts

Xue Wang

Role: primary

wxyxyuki@163.com

86-010-8778724

Other Identifiers

NCC5416

Identifier Type: -

Identifier Source: org_study_id